Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of DDN-A-0101 in Healthy Adults and Elderly
NCT06367426Phase 1Recruiting
- Sponsor
- Pharmacobio
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DDN-A-0101 in Alzheimer's disease (AD) (4 arms), sponsored by Pharmacobio. Primary endpoints: Assessment of safety and tolerability by monitoring vital signs, ECG, C-SSRS, and laboratory safety tests, Assessment of pharmacokinetics of Quercitrin in plasma and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
DDN-A-0101
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06367426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06367426.